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Abstract Over the past decade, research aiming to disentangle
the genetic underpinnings of late-onset Alzheimer’s disease has
mostly focused on the identification of common variants through
genome-wide association studies. The identification of several
new susceptibility genes through these efforts has reinforced the
importance of amyloid precursor protein and tau metabolism in
the cause of the disease and has implicated immune response,
inflammation, lipid metabolism, endocytosis/intracellular traf-
ficking, and cell migration in the cause of the disease. Ongoing
and future large-scale genome-wide association studies, transla-
tional studies, and next-generation whole genome or whole
exome sequencing efforts, hold the promise to map the specific
causative variants in these genes, to identify several additional
risk variants, including rare and structural variants, and to identify
novel targets for genetic testing, prevention, and treatment.
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Variation . Polymorphism . Genome-wide association study .
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Introduction
Late-onset Alzheimer’s disease (LOAD) typically begins
with the onset of symptoms after the age of 60 years
and evolves slowly from mildly impaired memory to
severe cognitive loss. At death, the most frequent path-
ological manifestations in the brain include extracellular
β-amyloid protein (Aβ) in diffuse and neuritic plaques
and intracellular deposits of hyperphosphorylated tau
protein, a microtubule assembly protein, in the form of
neurofibrillary tangles. Widespread loss of both neurons
and synapses also occurs [1].
An estimated 4.5 million Americans have LOAD. The
annual incidence of LOAD increases from 1 % at the age of
60–70 years to 10–30 % at 85 years and older [2]. As the US
population ages, it is expected that the number of LOAD cases
will increase to 16 million 20 million by 2050, with one in 45
Americans affected [3, 4]. A critical barrier to lessening the
impact of this disease is the limited development of drugs to
prevent or treat LOAD, which is mostly attributable to incom-
plete characterization of the basic underlying pathologic
mechanisms. Determining which genes and gene networks
contribute to LOAD risk would reveal basic pathogenic mech-
anisms, highlighting key proteins and pathways for drug
development (“druggable targets”), and inform the develop-
ment of genetic testing methods for identifying those at
greatest risk of LOAD when preventive measures become
available.
In recent years, the genetic analysis of LOAD has focused
on identification of common variants through genome-wide
association studies (GWAS) and has identified several novel
susceptibility genes implementing specific pathways in the
disease. This article reviews these studies, discusses their
potentials and limitations, and provides suggestions for future
research.
Data Source and Study Selection
The primary sources of the studies addressed in this
review were full-text articles and abstracts published in En-
glish in the PubMed database between 2010 and February
2013. The keywords used for searching PubMed were
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“dementia,” “Alzheimer’s disease,” “gene,” “genetics,” “epi-
genetics,” “endophenotype,” and “genome-wide association
study.” The abstracts retrieved were read to identify studies
addressing the topics included in this review. We also
performed a manual search of references cited in published
articles. The studies were read in their entirety to assess their
appropriateness for inclusion in this article.
Genetic Epidemiology of LOAD
A family history of dementia is one of the most important risk
factors for LOAD [5, 6]. Families multiply affected by LOAD
are at increased risk of dementia, but the distribution of
secondary cases is not consistent with Mendelian inheritance.
LOAD is more frequent among monozygotic twins than di-
zygotic twins [7–9], and first-degree relatives of patients with
LOAD have approximately twice the expected lifetime risk of
developing the disease. Heritabilities of 58–79 % for LOAD
indicate that in spite of progress made in identifying the
underpinnings of the disease, a substantial fraction of LOAD
is attributable to unknown genetic factors.
Apolipoprotein E Region
For more than a decade, only one genetic risk factor, the
APOE ε4 allele, located on chromosome band 19q13, was
an unequivocally established “susceptibility” gene in non-
Hispanic Whites of European ancestry. Apolipoprotein E
(ApoE) is a lipid-binding protein and is expressed in humans
as three common isoforms coded for by three alleles, ε2, ε3,
and ε4. A single APOE ε4 allele is associated with a twofold
to threefold increased risk; having two copies is associated
with a fivefold or more increased risk [10]. In addition, each
inherited APOE ε4 allele lowers the age at onset by 6–7 years
[11–18]. APOE ε4 is also associated with lower cognitive
performance, in particular the memory domain, is associated
with mild cognitive impairment [19–22], and is associated
with progression from mild cognitive impairment to dementia
[19–29]. Although the population attributable risk of APOE
ε4 is estimated at 20–50 % [30], the presence of ε4 is neither
necessary nor sufficient for development of the disease [31].
In ethnic groups other than non-Hispanic Whites, the associ-
ation between APOE and LOAD was largely inconsistent
across studies.
Findings from GWAS
At the beginning of the century, thousands of candidate-gene-
based association studies aiming to identify additional suscep-
tibility loci were performed, but only one gene, the sortilin-
related receptor (SORL1) [32], which is implicated in intracel-
lular trafficking of amyloid precursor protein (APP), could be
consistently replicated in independent datasets and implicated
in the disease. The main reasons for these inconsistencies
between studies are sample heterogeneity with differences in
linkage disequilibrium (LD) patterns and allele frequencies, and
small sample sizes, leading to limited power to detect small or
moderate effect sizes. In the past 5 years, technological ad-
vances in high-throughput genome-wide arrays have allowed
the hypothesis-free simultaneous examination of thousands to
millions of polymorphisms across the genome, and large col-
laborative efforts capitalizing on this technology have signifi-
cantly advanced knowledge of the genetic underpinnings of
LOAD and the pathways involved by identifying several novel
risk loci.
The major GWAS contributing to this gained knowledge
are summarized in Table 1. Most were performed in non-
Hispanic Whites of European ancestry. The first set of studies
identified CLU, PICALM, CR1, and BIN1 as susceptibility
loci [33–35]. Clusterin (Clu), also known as apolipoprotein J,
is a lipoprotein highly expressed in both the periphery and the
brain [36]. Like ApoE, it is involved in lipid transport [37].
Clu is also hypothesized to act as an extracellular chaperone
that influences Aβ aggregation and receptor-mediated Aβ
clearance by endocytosis [38]. Unlike for APOE, there are
no known coding variants that account for the observed ge-
netic association to CLU, suggesting that genetic variation in
expression levels may be responsible for the altered risk of
LOAD [38]. BIN1 (amphiphysin II) is a member of the Bin1/
amphiphysin/RVS167 (BAR) family of genes that are in-
volved in diverse cellular processes, including actin dynamics,
membrane trafficking, and clathrin-mediated endocytosis [39]
which affect APP processing and Aβ production or Aβ clear-
ance from the brain. Phosphatidylinositol-binding clathrin
assembly protein (PICALM) is also involved in clathrin-
mediated endocytosis and recruits clathrin and adaptor protein
complex 2 to sites of vesicle assembly [40]. CR1 is a cell-
surface receptor that is part of the complement system. It has
binding sites for complement factors C3b and C4b and is
involved in clearing immune complexes containing these two
proteins. Since Aβ oligomers can bind C3b, CR1 may partici-
pate in the clearance of Aβ. CR1 may also play a role in
neuroinflammation, which is a prominent feature inAlzheimer’s
disease [41]. Interestingly, Clu may play a role in this process as
an inhibitor [42]. In summary, this first set of GWAS identified
loci mainly clustering in four pathways, namely, immune re-
sponse, APP processing, lipid metabolism, and endocytosis/
intracellular trafficking.
The second set of large GWAS identified additional sus-
ceptibility genes (CD33, MS4A4A/MS4A4E/MS4A6E cluster,
ABCA7, CD2AP, and EPHA1) [43••, 44••]. In line with the
pathways identified by the first set of GWAS, all of these five
loci are likely involved in the immune system, whereas
ABCA7 is in addition involved in lipid metabolism and APP
processing (Table 2). The CD33 gene encodes a protein that is
381, Page 2 of 7 Curr Neurol Neurosci Rep (2013) 13:381
a member of a family of cell-surface immune receptors that
bind extracellular sialylated glycans and signal via a cytoplas-
mic domain called the immunoreceptor tyrosine inhibitory
motif [45, 46]. CD33 has primarily been studied in the pe-
ripheral immune system, where it is expressed on myeloid
progenitors and monocytes and also in the brain. In the pe-
riphery, CD33 appears to inhibit proliferation of myeloid cells
[47]. TheMS4A4A/MS4A4E/MS4A6E locus is part of a cluster
of 15 MS4A genes on chromosome 11 and encodes proteins
with multiple membrane-spanning domains that were initially
identified by their homology to CD20, a B-lymphocyte cell-
surface molecule. Little is known about the function of
MS4A4A gene products; however, like CD33, MS4A4A is
expressed on myeloid cells and monocytes and likely has an
immune-related function. EPHA1 encodes a member of the
ephrin family of cell-surface receptors which interact with
ephrin ligands on adjacent cells to modulate cell adhesion,
migration, and axon guidance and synapse formation and
plasticity. Although there is a substantial body of research
on the function of ephrin receptors in general, little is known
about the EPHA1 gene product. Like other ephrin receptors, it
regulates cell morphology and motility [48] and early work
implicated this receptor in regulating vascular morphogenesis
and angiogenesis [49]. EPHA1 knockout in mice results in
abnormal tail and reproductive tract development [50], but no
effects on the brain. Consistent with this notion, in mice,
expression is restricted to epithelial tissue. In humans, EPHA1
is expressed by CD4+ T lymphocytes [51], monocytes [52],
intestinal epithelium, and colon. Combined with the lack of
evidence for brain expression, this may suggest that, like
CD33, CR1, and MS4A4/MS4A6E, the role of the EPHA1
gene product in Alzheimer’s disease may be mediated though
the immune system. The CD2-associated protein gene
(CD2AP) encodes a scaffolding protein that binds directly to
actin [53], nephrin, and other proteins involved in cytoskeletal
organization. In the immune system, CD2AP is required for
synapse formation [54] in a process that involves clathrin-
dependent actin polymerization. ABCA7 is an integral trans-
membrane ATP-binding cassette (ABC) transporter belonging
to the ABC family of proteins that mediate the biogenesis of
high-density lipoprotein with cellular lipid and helical apoli-
poproteins [55]. It binds apolipoprotein A-I and functions in
apolipoprotein-mediated phospholipid and cholesterol efflux
from cells [56]. In addition, ABCA7 affects the transport of
other important proteins, including APP [56], through the cell
membrane and is involved in host defense through effects on
phagocytosis by macrophages of apoptotic cells [55].
In these large-scale GWAS performed in non-Hispanic
Whites of European ancestry, the most strongly associated
single-nucleotide polymorphisms (SNPs) at each locus other
than APOE demonstrated population attributable fractions
between 1.0 and 8.0 %, with effect sizes ranging from an odds
Table 1 Major Alzheimer’s disease (AD) genome-wide association studies (GWAS) performed
Study Ethnic group Sample size Genes identified outside APOE region
Lambert et al. [34] Caucasian Stage 1: 2,032 AD cases; 5,328 controls CLU, CR1
Stage 2: 3,978 AD cases; 3,297 controls
Harold et al. [33] Caucasian Stage 1: 3,941 AD cases; 7,848 controls CLU, PICALM
Stage 2: 2,023 AD cases; 2,340 controls
Seshadri et al. [35] Caucasian Stage 1: 3,006 AD cases; 4,642 controls BIN1, XOC3L2/BLOC1S3/MARK4,
CLU, PICALMStage 2: 2,032 AD cases; 5,328 controls
Stage 3: 3,333 AD cases; 6,995 controls
Naj et al. [44••] Caucasian Stage 1: 8,309 AD cases; 7,366 controls MS4A4A, CD2AP, CD33, EPHA1, CR1,
CLU, BIN1, PICALMStage 2: 3,531 AD cases; 3,565 controls
Hollingworth et al. [43••] Caucasian Stage 1: 6,688 AD cases; 13,685 controls ABCA7, MS4A6A/MS4A4E, EPHA1,
CD33, CD2APStage 2: 4,896 AD cases; 4,903 controls
Stage 3: 8,286 AD cases; 21,258 controls
Lee et al. [58] Caribbean Hispanic 549 AD cases; 544 controls CLU, PICALM, BIN1, CUGBP2, loci on 2p25.1;
3q25.2; 7p21.1; 10q23.1
Reitz et al. [59••] African American 1,968 AD cases; 3,928 controls ABCA7, intergenic locus on 5q35.2
Table 2 Major pathways identified by GWAS
Pathway Gene












CLU, PICALM, BIN1, EPHA1, MS4A4A/
MS4A6E, CD33, CD2AP
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ratio of 1.16 to an odds ratio of 1.20, i.e., much smaller than
for APOE [57]. In the largest GWAS performed to date in
Caribbean Hispanics [58], associations inCLU, PICALM, and
BIN1 were replicated and several additional loci on 2p25.1,
3q25.2, 7p21.1, and 10q23.1—which could be replicated in
an independent cohort of non-Hispanic Whites of European
ancestry from the National Institute on Aging Late-Onset
Alzheimer’s Disease Family Study (NIA-LOAD)—were ob-
served. Finally, in the largest GWAS of African Americans
performed, Reitz et al. [59••] identified ABCA7 as a major
susceptibility locus in this ethnic group. Interestingly, in con-
trast to all GWAS loci identified in Caucasians, in African
Americans the ABCA7 locus had an effect size as strong as
that of APOE ε4 (i.e., a 70–80 % increase in risk compared
with a 10–20 % increase in risk through the GWAS loci
observed in Whites). Although this finding may represent a
winner’s curse (i.e., inflation of the estimated effect in a
discovery set in relation to follow-up studies) and needs to
be confirmed by independent studies in African Americans
and functional methods, it may have major implications for
developing targets for genetic testing, prevention, and treat-
ment in this ethnic group if proven true. In addition, this study
confirmed APOE as a susceptibility gene in this ethnic group,
evidence for which prior to this study had been inconsistent
across studies, and also replicated CR1, BIN1, EPHA1, and
CD33.
Discussion
The recent GWAS for LOAD using large numbers of cases
and controls identified several novel susceptibility loci that are
biologically plausible, cluster in specific pathways, and have
significantly advanced the understanding of the pathogenic
mechanism underlying the disease. Common to all novel loci
in non-Hispanic Whites of European ancestry is the modest
effect size with odds ratio ranging from 1.1 to 1.5 leaving the
APOE ε4 allele by far the strongest risk factor. In contrast, in
the largest GWAS performed to date in African Americans,
the ABCA7 locus was observed to have an effect size similar to
that of APOE (70–80 % increase in risk). The population
attributable risk of each of the non-APOE loci is estimated
to be 1–8 %. However, this estimate will change with eluci-
dation of the number, allele frequencies, and risk effects of the
true functional variants at each locus, and the detection of
additional common and rare risk variants and patterns of
epistasis.
Replication in independent datasets—if possible across
different ethnic groups—and functional validation of the loci
identified by GWAS is crucial for several reasons. First,
GWAS are not designed to identify the specific causative
variants, but rather are designed screen the genome, capitaliz-
ing on the LD between genotyped SNPs and the potentially
causative variants [60]. As LD can extend over large intervals,
the true genetic effectors may be located considerably far
away from the SNP showing the disease association, limiting
the ability to detect true associations from GWAS. The devel-
opment of high-throughput genotyping arrays, which have
increased the number of genotyped markers to several mil-
lions, has decreased this problem to some extent, but not
entirely, depending on the LD pattern in the region. Second,
signals selected on the basis of statistical significance thresh-
olds in underpowered settings are often subject to the winner’s
curse (bias away from the null in the estimated effect of a
newly identified allele on disease) [61–63], and replication
can help produce a more accurate, unbiased estimate of the
genetic effect of a locus. Third, the probability that an ob-
served association truly exists depends on the power to detect
the association, which in turn is a function of minor allele
frequency, effect size, sample size, and the observed p value.
The distribution of effect sizes of true associations in complex
diseases is unknown, but it is likely that most of the large
effects in LOAD GWAS have been identified, whereas most
of the smaller effects remain to be discovered. The signifi-
cance threshold needed to preserve the genome-wide type I
error rate in studies of individuals with European ancestry is
estimated at 5×10−7–1×10−8 [64, 65]. This threshold is even
lower in ethnic groups with greater genetic diversity such as
Hispanics, Africans, and African Americans and, consequent-
ly, most individual GWAS do not have enough power to
distinguish false positives from false negatives. Finally, repli-
cation in a population with different environmental or genetic
backgrounds may—if assessed in a population with a lower
extent of LD such as Africans—help narrow down the loca-
tion of the causative variant. In addition, it allows one to
determine the generalizability of the observed association.
However, when the aim is to replicate an observed associa-
tion, it has to be kept in mind that there are several reasons for
the observation of no association, including differences in
allele frequencies or LD patterns across populations, or allelic
or locus heterogeneity.
There are several additional approaches that can address
some of these issues inherent to GWAS. Reclassifying sample
subjects into more homogeneous subgroups, for example,
based on endophenotypes, can reduce phenotypic heteroge-
neity and increase the power to detect true associations.
Gene-based association studies, which consider association
between a trait and all markers within a gene rather than each
marker individually, can be more powerful than traditional
individual-SNP-basedGWAS. For example, if a gene contains
more than one causative variant, then several SNPs within that
gene might showmarginal levels of significance that are often
indistinguishable from random noise in the initial GWAS
results. If the effects of all SNPs in a gene are combined into
a test statistic and correction is made for LD, the gene-based
test might be able to detect these effects. Similarly, genome-
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wide haplotype-based association studies can characterize loci
not detected by univariate analyses. Such gene-based or
haplotype-based analyses led to the discovery of NARS2,
FRMD6, and FRMD4A as susceptibility loci [66, 67], the
latter of which is immediately adjacent to GAB2. Identifica-
tion and examination of regions with runs of homozygosity
(i.e., excess burden of homozygous markers) can help identify
recessive causative genes. Evidence is accumulating that a
substantial part of the missing genetic variability could be
due to epistatic effects or gene–environment interactions.
Thus, exploration of gene–gene and gene–environment inter-
actions can identify novel variants not detected by individual
testing of SNPs. However, such studies require large samples
sizes and/or large effect sizes to achieve adequate power.
Although the latest GWAS arrays include dense SNP maps
of several million SNPs with minor allele frequency down to
1 % and novel functional exonic variants that were identified
through sequencing of thousands of exomes, they are limited
in their ability to detect associations with variants not tagged
by the genotyped SNPs. In addition, they are limited in their
ability to identify structural variants or rare variants with
minor allele frequency of less than 1 %. However, both rare
and structural variants are increasingly recognized as being
implicated in complex disease [68]. In fact, two recent studies
that performed genome sequencing followed by imputation of
identified variants in independent datasets implicated the trig-
gering receptor expressed onmyeloid cells 2 gene (TREM2) in
Alzheimer’s disease by identifying a causative rare missense
mutation (rs75932628) resulting in an R47H substitution af-
fecting the gene’s anti-inflammatory function [69•, 70•]. Ad-
ditional sequencing studies identified rare causative variants
in the nicastrin gene (NCSTN) encoding an obligatory com-
ponent of the γ-secretase complex involved in splicing of
APP [71] as well as CLU [72]. Although individual rare
variants may have an effect size large enough to cause disease,
the accumulation of several rare variants each with small or
modest effect sizes may cross the susceptibility threshold.
Ongoing and future large-scale next-generation whole exome
or whole genome sequencing techniques will fill this gap and
further provide the means to identify the specific causative
variants in the genes/regions identified by GWAS. Although
appropriate algorithms for the statistical and bioinformatic
analysis of sequencing data, in particular for whole genome
sequencing data and whole exome or whole genome sequenc-
ing data derived from families, still need to be developed and
implemented, the recent identification of rare variants in CLU,
NCSTN, and TREM2 in LOAD that also cluster in amyloid
processing and immune-response/inflammation pathways and
were missed by the GWAS but identified by sequencing studies
clearly belie the common disease–common variant hypothesis
and prove the necessity of approaches with the ability to detect
rare variants [69•, 70•, 71, 72]. Once causative variants are
identified, functional studies can assess the pathogenic effects
of the variants and characterize the molecular pathways in
which they are involved or with which they interact, further
implicating the gene in the disease and potentially providing
targets for effective intervention.
Conclusions and Future Directions
Over the past 10 years, studies capitalizing on high-throughput
genome technologies have significantly advanced knowledge
of the genetic underpinnings of LOAD. GWAS have identified
several susceptibility genes, and sequencing studies have iden-
tified specific causative variants in these genes, but have also
provided invaluable evidence for an involvement of rare vari-
ants in this complex disease, overturning the common disease–
common variant hypothesis that had long defined the genetic
research of complex diseases. Ongoing and future large-scale
next-generation sequencing approaches (both hypothesis-
driven and hypothesis-free) are likely to disentangle a signifi-
cant part of the missing heritability of LOAD, and have the
potential to identify targets for genetic testing, prevention, and
treatment.
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